Cookies
This website uses cookies to improve your user experience.
By using the site, you agree to our use of cookies.
Click here for more information about how we use cookies.
Mark Cragg is Professor of Experimental Cancer Biology in the School of Cancer Sciences at the University of Southampton Faculty of Medicine. His research concerns how therapeutics result in tumour regression with a focus on antibodies and small molecules, with a particular interest in Fc receptors and TNFR family members. The aim is to understand how these therapeutics delete tumour cells, how resistance occurs, and how it might be overcome through antibody engineering. In his most recent work, Professor Cragg has studied antibodies directed to immunostimulatory receptors as an untapped source for immunotherapy, combining structural biology, molecular dynamics simulations, and protein engineering to elicit immune stimulation. Throughout the strategy undertaken is highly translational with iterative cycling between in vitro experiments, appropriate in vivo model systems, and primary clinical material. He sits on advisory boards for several charities and institutes and was elected a member of the Academy of Medical Sciences in 2024.

BACR is a registered charity in England and Wales (289297)
Registered address:
c/o Leeds Institute of Medical Research, Clinical Sciences Building
St James’s University Hospital, Becket Street, Leeds LS9 7TF
Home / Privacy Policy & Cookies / Terms of use / Site map / Admin
© 2018 - 2026 BACR - The British Association for Cancer Research. All rights reserved.
This website uses cookies to improve your user experience.
By using the site, you agree to our use of cookies.
Click here for more information about how we use cookies.